Puma Biotechnology, Inc. (PBYI) Earnings History
Annual and quarterly earnings data from 2007 to 2025
Loading earnings history...
EPS Growth Rates (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 74.5% | 16.3% | 13.6% |
| 2024 | 72.1% | 13.4% | 13.1% |
| 2023 | 73.4% | 13.9% | 9.2% |
| 2022 | 75.8% | 10.4% | 0.0% |
| 2021 | 74.8% | 0.5% | -11.5% |
Download Data
Export PBYI earnings history in CSV or JSON format
Free sign-in required to download data
Puma Biotechnology, Inc. (PBYI) Earnings Overview
As of March 1, 2026, Puma Biotechnology, Inc. (PBYI) reported trailing twelve-month net income of $31M, reflecting -0.0% year-over-year growth. The company earned $0.60 per diluted share over the past four quarters, with a net profit margin of 0.1%.
Looking at the long-term picture, PBYI's historical earnings data spans multiple years. The company achieved its highest annual net income of $31M in fiscal 2025, representing a new all-time high.
Puma Biotechnology, Inc. maintains positive profitability with a gross margin of 0.7%, operating margin of 0.2%, and net margin of 0.1%. The company continues to generate positive earnings from operations. View revenue history →
Compared to industry peers including RVMD (-$1.13B net income), INCY ($1.29B net income, 0.3% margin), GMAB ($6.57B net income, 0.4% margin), PBYI has comparable earnings metrics. Compare PBYI vs RVMD →
Peer Comparison
Earnings metrics vs industry competitors
Historical Data
19 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $31M | +2.8% | $37M | $0.61 | 13.6% | 16.3% |
| 2024 | $30M | +40.2% | $31M | $0.62 | 13.1% | 13.4% |
| 2023 | $22M | +1079450.0% | $33M | $0.45 | 9.2% | 13.9% |
| 2022 | $2,000 | +100.0% | $24M | $0.02 | 0.0% | 10.4% |
| 2021 | -$29M | +51.5% | $1M | $-0.72 | -11.5% | 0.5% |
| 2020 | -$60M | +20.6% | -$30M | $-1.52 | -26.7% | -13.5% |
| 2019 | -$76M | +33.5% | -$76M | $-2.13 | -27.8% | -27.8% |
| 2018 | -$114M | +61.1% | -$95M | $-2.99 | -45.3% | -37.7% |
| 2017 | -$292M | -5.8% | -$292M | $-7.86 | -1054.2% | -1055.6% |
| 2016 | -$276M | -15.3% | -$277M | $-8.29 | - | - |
See PBYI's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs PBYI Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare PBYI vs AGIO
See how PBYI stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is PBYI growing earnings?
PBYI TTM EPS: $0.60. Net income: $31M. Earnings growth: -0.0%.
What are PBYI's profit margins?
Puma Biotechnology, Inc. net margin is +0.1%, with operating margin at +0.2%. Below-average margins reflect competitive or cost pressures.
How consistent are PBYI's earnings?
PBYI earnings data spans 2007-2025. The current earnings trend is -0.0% YoY. Historical data enables comparison across business cycles.